Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for PROLIA
- Preserving Geriatric Muscle With an Osteoporosis Medication
- Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
- Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
- Randomized, Double-Blind, Parallel Design, 2-arm,Multicenter Study Assessing the Biosimilarity of AVT03 and US-Prolia® in Postmenopausal Women With Osteoporosis
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
- FITMI - First In Treating Male Infertility
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
- Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
- The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy
- Comparative Efficacy and Safety Study of RGB-14-P and Prolia in Women With Postmenopausal Osteoporosis
- A Study to Evaluate LY06006 and Prolia in Healthy Adults
- Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
- A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis
- Romosozumab/Denosumab Study for Premenopausal IOP
- Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults
- Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.
- A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
- Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Women
- Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .
- The DENOCHARCOT Trial
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects
- Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
- The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults
- Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
- RANKL Inhibition and Mammographic Breast Density
- Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
- Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
- The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
- Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
- Markers of Osteoporosis in Cystic Fibrosis
- Denosumab Sequential Therapy
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
- RANKL Inhibition and Breast Tissue Biomarkers
- Comparative Antiresorptive Efficacy Discontinuation of Denosumab
- Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
- Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
- Bisphosphonates for Prevention of Post-Denosumab Bone Loss
- Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
- Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
- Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis
- Denosumab and Male Infertility: a RCT
- Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
- Denosumab Versus Bisphosphonates (Alendronate) in GIOP
- Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
- Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients
- A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
- The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty
- Preventing Osteoporosis Using Denosumab
- 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
- Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
- Osteoclast Inhibition and Bone Formation
- Denosumab Safety Assessment in Multiple Observational Databases
- Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
- Longjohn Amgen Study - Effect of Denosumab...
- TNFSF11 Inhibition and Fertility: a Prospective Study
- Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
- Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
- Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
- The Efficacy of Denosumab in Active Crohn's Disease
- Denosumab for Treating Periprosthetic Osteolysis.
- Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
- Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.
- The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab
- Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
- Denosumab Administration After Spinal Cord Injury
- Effect of RANKL Inhibition on UV-induced Immunosuppression
- Denosumab for Breast Cancer With Bone Mets
- RA Denosumab on Bone Microstructure Study
- Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
- Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty
- Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
- Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass
- Denosumab in Primary Hyperparathyroidism
- Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis
- Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
- Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty
- Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Clinical trials list
click for details